N. Petrovsky

This study shows that a vaccine targeting the L9 epitope of CSP in Plasmodium falciparum provides protection against blood-stage malaria in mice.

This study develops a recombinant SARS-CoV-2 spike protein vaccine, Covax-19, formulated with Advax-SM adjuvant, showing protection against COVID-19 in mice and ferrets.

This study shows that combining adjuvants with a fungal recombinant protein vaccine enhances protection against Blastomyces dermatitidis infection by inducing specific T cell responses.

This study shows that a novel adjuvant can enable same-day protection against a lethal influenza virus challenge through IgM neutralizing antibodies.

This study evaluates Advax adjuvant formulations for tuberculosis vaccine efficacy, showing they provide strong protection without causing inflammation or reactogenicity.

This paper develops a malaria vaccine targeting the CIS43 epitope on CSP using Qβ VLPs, showing high immunogenicity and partial protection in mice and macaques.

This paper shows that a mucosal vaccine induces lung-resident memory T cells expressing IL-17, which protect against tuberculosis, and that IL-17 is critical for this protection.